Are you looking for information on the MAGNITUDE-3 trial results for Attruby (acoramidis) in ATTR-CM?
The search results available don't include specific details about the MAGNITUDE-3 trial by name. However, there is solid data from the phase 3 ATTRibute-CM trial for acoramidis that's worth knowing about. Here's what the Show Full Answer
Are you looking for information on the MAGNITUDE-3 trial results for Attruby (acoramidis) in ATTR-CM?
The search results available don't include specific details about the MAGNITUDE-3 trial by name. However, there is solid data from the phase 3 ATTRibute-CM trial for acoramidis that's worth knowing about. Here's what the ATTRibute-CM phase 3 trial found for acoramidis (Attruby):
- 49% lower risk of cardiovascular death or repeat hospitalizations compared to placebo
- 53 fewer serious heart events per 100 people treated vs. placebo
- Benefits began within the first month and grew over time
- Continued benefits seen at 42 months for those who stayed on the drug
The FDA approved acoramidis in 2024 for both wild-type and hereditary ATTR-CM. It's taken as a tablet, usually twice daily.
Common side effects include diarrhea and upper abdominal pain. Rare side effects may involve temporary changes in kidney function markers, so monitoring is important.
For the most current MAGNITUDE-3 specific results, checking with a specialist or visiting a clinical trial database would be the best next step.
July 7
Join
Your Privacy Choices
